Crescendo Biologics Appoints Matthew Roe as Chief Business Officer

June 22, 2011

CAMBRIDGE, England, June 21, 2011 /PRNewswire/ –

Crescendo Biologics Limited (Crescendo) today announces the appointment
of Matthew Roe as Chief Business Officer. Matthew joins Crescendo from
Genzyme Corporation where he was Senior Director, Business Development &

During a 23-year career at Genzyme, Matthew was active in licensing,
alliance management, acquisition, divestment, and sales and marketing, and
saw the corporation develop from an entrepreneurial start-up to a leading
multi-national biotechnology company. He negotiated and managed multiple
agreements for drug delivery technologies in the USA, Europe and Japan and
was also a core team member on the divestment of Genzyme’s Pharmaceuticals

Mike Romanos, CEO of Crescendo said: “Matthew’s track record in business
development speaks for itself. He has an exceptional depth of experience in
business strategy and in implementing agreements across multiple
territories. I look forward to working with him as we build on the
significant advances we have made at Crescendo and position the Company to
deliver real value from its world class, proprietary technology platforms.”

Matthew Roe, CBO of Crescendo said: “The monoclonal antibody market is
rapidly growing and continues to be a major focus for the pharma industry.
Companies are searching for new platforms and approaches, particularly in
the area of antibody fragments. Crescendo’s technology platform, IP and
insight create a strong foundation from which to make a significant impact
in the field and I am delighted to be joining the Company’s management team
as it seeks to grow to become a leader in next-generation antibody

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment
technologies to the development of new targeted therapeutics. The Crescendo
transgenic mouse platform under development has the potential to rapidly and
predictably generate high-affinity human heavy chain antibodies that readily
yield VH fragments that have no requirement for humanisation. This is
combined with a powerful in vitro ribosome display technology which offers
significant advantages over existing approaches in antibody optimisation. VH
fragments provide great flexibility as a starting point for the development
of new targeted therapeutics combining the specificity and binding affinity
of antibodies with certain desirable characteristics of small molecules.

Crescendo’s technologies were invented by scientists at the Babraham
Institute, Cambridge (UK). The Company has raised GBP4.5 million in seed
funding from leading life sciences investors, Sofinnova Partners with Aitua,
Avlar BioVentures and the Rainbow Seed Fund also participating.



        Mike Romanos/Amanda Bettison
        Crescendo Biologics
        Tel: +44(0)1223-497140
        Email: mromanos/abettison@crescendobiologics.com

        Chris Gardner
        Citigate Dewe Rogerson
        Tel: +44(0)207-638-9571
        Email: chris.gardner@citigatedr.co.uk

SOURCE Crescendo Biologics Limited

Source: newswire

comments powered by Disqus